isopropyl glycidyl ether: RN & structure given in first source
ID Source | ID |
---|---|
PubMed CID | 19920 |
CHEMBL ID | 1487011 |
SCHEMBL ID | 39030 |
MeSH ID | M0228468 |
Synonym |
---|
EN300-22498 |
IGE , |
isopropyl glycidyl ether |
glycidyl isopropyl ether |
4016-14-2 |
propane,2-epoxy-3-isopropoxy- |
(isopropoxymethyl)oxirane |
nsc-4127 |
wln: t3otj b1oy1&1 |
3-isopropyloxypropylene oxide |
nsc4127 |
oxirane, [(1-methylethoxy)methyl]- |
3-isopropoxy-1,2-epoxypropane |
nci-c56439 |
propane, 1,2-epoxy-3-isopropoxy- |
nsc-46562 |
nsc46562 |
ccris 2631 |
hsdb 4302 |
isopropyl glycidyl ether ige |
1,2-epoxy-3-isopropoxypropane |
2,3-epoxypropyl isopropyl ether |
nsc 46562 |
((1-methylethoxy)methyl)oxirane |
nsc 4127 |
isopropyl epoxypropyl ether |
oxirane, ((1-methylethoxy)methyl)- |
2,3-epoxypropyl-isopropyl ether |
ai3-52929 |
brn 0103028 |
einecs 223-672-9 |
NCGC00091815-01 |
glycidyl isopropyl ether, 98% |
2-(isopropoxymethyl)oxirane |
2-(propan-2-yloxymethyl)oxirane |
inchi=1/c6h12o2/c1-5(2)7-3-6-4-8-6/h5-6h,3-4h2,1-2h3 |
nwluzgjdezbbrh-uhfffaoysa- |
AKOS000196880 |
MLS002454412 |
smr001372011 |
G0255 |
2-[(propan-2-yloxy)methyl]oxirane |
STK802341 |
NCGC00091815-02 |
HMS3039F15 |
unii-1v3116630g |
oxirane, 2-((1-methylethoxy)methyl)- |
1v3116630g , |
dtxcid705480 |
dtxsid6025480 , |
tox21_200038 |
cas-4016-14-2 |
NCGC00257592-01 |
isopropyl glycidyl ether [hsdb] |
(isopropyloxymethyl)oxirane |
glycidyl isopropyl ether, (+/-)- |
2-((1-methylethoxy)methyl)oxirane |
AKOS017283448 |
CHEMBL1487011 |
isopropylglycidyl ether |
2-[(1-methylethoxy)methyl]oxirane |
BBL027498 |
SCHEMBL39030 |
oxirane, 2-[(1-methylethoxy)methyl]- |
2-(isopropoxymethyl)oxirane # |
1,2-epoxy-3-iso-propoxypropane |
glycidyl isopropyl ether purum |
mfcd00005139 |
glycidyl isopropyl ether, purum, >=98.0% (gc) |
FT-0761964 |
F0001-1133 |
Q2803610 |
VS-08554 |
glycidylisopropylether |
E78219 |
Z147642824 |
SY051643 |
Excerpt | Reference | Relevance |
---|---|---|
"The isopropyl glycidyl ether treatment of wood was effective in decreasing formation of phenoxyl radicals upon UV irradiation and thus protecting wood from photodiscoloration." | ( Modification of wood with isopropyl glycidyl ether and its effects on decay resistance and light stability. Chang, HT; Chang, ST, 2006) | 1.11 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.0171 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
TDP1 protein | Homo sapiens (human) | Potency | 4.6109 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 61.0257 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 60.9988 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 0.4867 | 0.0002 | 29.3054 | 16,493.5996 | AID743075 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 79.4328 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 61.2754 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
geminin | Homo sapiens (human) | Potency | 12.4347 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (11.11) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 1 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.84) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |